Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features

Atsushi Osoegawa, Ichiro Yoshino, Takuro Kometani, Masafumi Yamaguchi, Toshifumi Kameyama, Tomofumi Yohena, Yoshihiko Maehara

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

BACKGROUND. Decreased expression of p27, which is an inhibitor of cyclin-dependent kinase, is associated with cancer aggressiveness. It is believed that Jun activation domain-binding protein 1 (Jab1) plays a role in p27 degradation in a manner that is independent from the role played by S-phase kinase-associated protein 2 (Skp2). To examine the clinical significance of Jab1 in nonsmall cell lung cancer (NSCLC), the protein expression of Jab1 in tumor tissues was investigated with regard to the expression of p27 and Skp2. METHODS. The clinicopathologic features and immunohistochemical expression levels of Jab1, p27, and Skp2 proteins were studied in 138 specimens from patients who underwent surgical resection for NSCLC. Survival analyses were performed by using the Kaplan-Meier method and Cox regression models. RESULTS. High Jab1 expression (>50% of cancer cell nuclei stained) was observed in 81 specimens (59%). In Skp2-negative specimens (n = 81), an inverse correlation between the protein expression of p27 and Jab1 was observed both with the chi-square test (P = .02) and with the Mann-Whitney U test (P = .02). High Jab1 expression levels were related to poor outcomes in 118 patients who underwent complete resection, with a 5-year overall survival rate of 43.9% for patients who had high Jab1 expression and 63.1% for patients who had low Jab1 expression (P = .01). This difference was greater in patients who had Skp2-negative specimens (51.9% vs. 79.3% (P = .02), but it was not significant in patients who had Skp2-positive specimens. The multivariate analysis revealed that Jab1 expression was an independent prognostic factor for survival in patients with NSCLC (relative risk, 2.247; P = .01). CONCLUSIONS. The current results showed for the first time that high Jab1 protein expression is related to poor outcome in patients with NSCLC and that this protein may be a target of therapy in NSCLC.

Original languageEnglish
Pages (from-to)154-161
Number of pages8
JournalCancer
Volume107
Issue number1
DOIs
Publication statusPublished - Jul 1 2006

Fingerprint

Non-Small Cell Lung Carcinoma
S-Phase Kinase-Associated Proteins
Carrier Proteins
Proteins
Neoplasms
Cyclin-Dependent Kinases
Chi-Square Distribution
Survival Analysis
Nonparametric Statistics
Cell Nucleus
Proportional Hazards Models
Multivariate Analysis
Survival Rate
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features. / Osoegawa, Atsushi; Yoshino, Ichiro; Kometani, Takuro; Yamaguchi, Masafumi; Kameyama, Toshifumi; Yohena, Tomofumi; Maehara, Yoshihiko.

In: Cancer, Vol. 107, No. 1, 01.07.2006, p. 154-161.

Research output: Contribution to journalArticle

Osoegawa, Atsushi ; Yoshino, Ichiro ; Kometani, Takuro ; Yamaguchi, Masafumi ; Kameyama, Toshifumi ; Yohena, Tomofumi ; Maehara, Yoshihiko. / Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features. In: Cancer. 2006 ; Vol. 107, No. 1. pp. 154-161.
@article{a58083f12ef641aca7e5f115e9ff84fd,
title = "Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features",
abstract = "BACKGROUND. Decreased expression of p27, which is an inhibitor of cyclin-dependent kinase, is associated with cancer aggressiveness. It is believed that Jun activation domain-binding protein 1 (Jab1) plays a role in p27 degradation in a manner that is independent from the role played by S-phase kinase-associated protein 2 (Skp2). To examine the clinical significance of Jab1 in nonsmall cell lung cancer (NSCLC), the protein expression of Jab1 in tumor tissues was investigated with regard to the expression of p27 and Skp2. METHODS. The clinicopathologic features and immunohistochemical expression levels of Jab1, p27, and Skp2 proteins were studied in 138 specimens from patients who underwent surgical resection for NSCLC. Survival analyses were performed by using the Kaplan-Meier method and Cox regression models. RESULTS. High Jab1 expression (>50{\%} of cancer cell nuclei stained) was observed in 81 specimens (59{\%}). In Skp2-negative specimens (n = 81), an inverse correlation between the protein expression of p27 and Jab1 was observed both with the chi-square test (P = .02) and with the Mann-Whitney U test (P = .02). High Jab1 expression levels were related to poor outcomes in 118 patients who underwent complete resection, with a 5-year overall survival rate of 43.9{\%} for patients who had high Jab1 expression and 63.1{\%} for patients who had low Jab1 expression (P = .01). This difference was greater in patients who had Skp2-negative specimens (51.9{\%} vs. 79.3{\%} (P = .02), but it was not significant in patients who had Skp2-positive specimens. The multivariate analysis revealed that Jab1 expression was an independent prognostic factor for survival in patients with NSCLC (relative risk, 2.247; P = .01). CONCLUSIONS. The current results showed for the first time that high Jab1 protein expression is related to poor outcome in patients with NSCLC and that this protein may be a target of therapy in NSCLC.",
author = "Atsushi Osoegawa and Ichiro Yoshino and Takuro Kometani and Masafumi Yamaguchi and Toshifumi Kameyama and Tomofumi Yohena and Yoshihiko Maehara",
year = "2006",
month = "7",
day = "1",
doi = "10.1002/cncr.21961",
language = "English",
volume = "107",
pages = "154--161",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features

AU - Osoegawa, Atsushi

AU - Yoshino, Ichiro

AU - Kometani, Takuro

AU - Yamaguchi, Masafumi

AU - Kameyama, Toshifumi

AU - Yohena, Tomofumi

AU - Maehara, Yoshihiko

PY - 2006/7/1

Y1 - 2006/7/1

N2 - BACKGROUND. Decreased expression of p27, which is an inhibitor of cyclin-dependent kinase, is associated with cancer aggressiveness. It is believed that Jun activation domain-binding protein 1 (Jab1) plays a role in p27 degradation in a manner that is independent from the role played by S-phase kinase-associated protein 2 (Skp2). To examine the clinical significance of Jab1 in nonsmall cell lung cancer (NSCLC), the protein expression of Jab1 in tumor tissues was investigated with regard to the expression of p27 and Skp2. METHODS. The clinicopathologic features and immunohistochemical expression levels of Jab1, p27, and Skp2 proteins were studied in 138 specimens from patients who underwent surgical resection for NSCLC. Survival analyses were performed by using the Kaplan-Meier method and Cox regression models. RESULTS. High Jab1 expression (>50% of cancer cell nuclei stained) was observed in 81 specimens (59%). In Skp2-negative specimens (n = 81), an inverse correlation between the protein expression of p27 and Jab1 was observed both with the chi-square test (P = .02) and with the Mann-Whitney U test (P = .02). High Jab1 expression levels were related to poor outcomes in 118 patients who underwent complete resection, with a 5-year overall survival rate of 43.9% for patients who had high Jab1 expression and 63.1% for patients who had low Jab1 expression (P = .01). This difference was greater in patients who had Skp2-negative specimens (51.9% vs. 79.3% (P = .02), but it was not significant in patients who had Skp2-positive specimens. The multivariate analysis revealed that Jab1 expression was an independent prognostic factor for survival in patients with NSCLC (relative risk, 2.247; P = .01). CONCLUSIONS. The current results showed for the first time that high Jab1 protein expression is related to poor outcome in patients with NSCLC and that this protein may be a target of therapy in NSCLC.

AB - BACKGROUND. Decreased expression of p27, which is an inhibitor of cyclin-dependent kinase, is associated with cancer aggressiveness. It is believed that Jun activation domain-binding protein 1 (Jab1) plays a role in p27 degradation in a manner that is independent from the role played by S-phase kinase-associated protein 2 (Skp2). To examine the clinical significance of Jab1 in nonsmall cell lung cancer (NSCLC), the protein expression of Jab1 in tumor tissues was investigated with regard to the expression of p27 and Skp2. METHODS. The clinicopathologic features and immunohistochemical expression levels of Jab1, p27, and Skp2 proteins were studied in 138 specimens from patients who underwent surgical resection for NSCLC. Survival analyses were performed by using the Kaplan-Meier method and Cox regression models. RESULTS. High Jab1 expression (>50% of cancer cell nuclei stained) was observed in 81 specimens (59%). In Skp2-negative specimens (n = 81), an inverse correlation between the protein expression of p27 and Jab1 was observed both with the chi-square test (P = .02) and with the Mann-Whitney U test (P = .02). High Jab1 expression levels were related to poor outcomes in 118 patients who underwent complete resection, with a 5-year overall survival rate of 43.9% for patients who had high Jab1 expression and 63.1% for patients who had low Jab1 expression (P = .01). This difference was greater in patients who had Skp2-negative specimens (51.9% vs. 79.3% (P = .02), but it was not significant in patients who had Skp2-positive specimens. The multivariate analysis revealed that Jab1 expression was an independent prognostic factor for survival in patients with NSCLC (relative risk, 2.247; P = .01). CONCLUSIONS. The current results showed for the first time that high Jab1 protein expression is related to poor outcome in patients with NSCLC and that this protein may be a target of therapy in NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=33745309536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745309536&partnerID=8YFLogxK

U2 - 10.1002/cncr.21961

DO - 10.1002/cncr.21961

M3 - Article

C2 - 16721818

AN - SCOPUS:33745309536

VL - 107

SP - 154

EP - 161

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -